1152 related articles for article (PubMed ID: 32361713)
1. Human chimeric antigen receptor macrophages for cancer immunotherapy.
Klichinsky M; Ruella M; Shestova O; Lu XM; Best A; Zeeman M; Schmierer M; Gabrusiewicz K; Anderson NR; Petty NE; Cummins KD; Shen F; Shan X; Veliz K; Blouch K; Yashiro-Ohtani Y; Kenderian SS; Kim MY; O'Connor RS; Wallace SR; Kozlowski MS; Marchione DM; Shestov M; Garcia BA; June CH; Gill S
Nat Biotechnol; 2020 Aug; 38(8):947-953. PubMed ID: 32361713
[TBL] [Abstract][Full Text] [Related]
2. M1 polarization enhances the antitumor activity of chimeric antigen receptor macrophages in solid tumors.
Huo Y; Zhang H; Sa L; Zheng W; He Y; Lyu H; Sun M; Zhang L; Shan L; Yang A; Wang T
J Transl Med; 2023 Mar; 21(1):225. PubMed ID: 36978075
[TBL] [Abstract][Full Text] [Related]
3. Engineered CAR-Macrophages as Adoptive Immunotherapies for Solid Tumors.
Sloas C; Gill S; Klichinsky M
Front Immunol; 2021; 12():783305. PubMed ID: 34899748
[TBL] [Abstract][Full Text] [Related]
4. Sophisticated genetically engineered macrophages, CAR-Macs, in hitting the bull's eye for solid cancer immunotherapy approaches.
Unver N
Clin Exp Med; 2023 Nov; 23(7):3171-3177. PubMed ID: 37278931
[TBL] [Abstract][Full Text] [Related]
5. CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy.
Pan K; Farrukh H; Chittepu VCSR; Xu H; Pan CX; Zhu Z
J Exp Clin Cancer Res; 2022 Mar; 41(1):119. PubMed ID: 35361234
[TBL] [Abstract][Full Text] [Related]
6. PTK7-Targeting CAR T-Cells for the Treatment of Lung Cancer and Other Malignancies.
Jie Y; Liu G; Feng L; Li Y; E M; Wu L; Li Y; Rong G; Li Y; Wei H; Gu A
Front Immunol; 2021; 12():665970. PubMed ID: 34475869
[TBL] [Abstract][Full Text] [Related]
7. Enhanced Cancer Immunotherapy by Chimeric Antigen Receptor-Modified T Cells Engineered to Secrete Checkpoint Inhibitors.
Li S; Siriwon N; Zhang X; Yang S; Jin T; He F; Kim YJ; Mac J; Lu Z; Wang S; Han X; Wang P
Clin Cancer Res; 2017 Nov; 23(22):6982-6992. PubMed ID: 28912137
[No Abstract] [Full Text] [Related]
8. Manipulating macrophage polarization in cancer patients: From nanoparticles to human chimeric antigen receptor macrophages.
Santoni M; Massari F; Montironi R; Battelli N
Biochim Biophys Acta Rev Cancer; 2021 Aug; 1876(1):188547. PubMed ID: 33932561
[TBL] [Abstract][Full Text] [Related]
9. Effects of CSF1R-targeted chimeric antigen receptor-modified NK92MI & T cells on tumor-associated macrophages.
Zhang P; Zhao S; Wu C; Li J; Li Z; Wen C; Hu S; An G; Meng H; Zhang X; Yang L
Immunotherapy; 2018 Aug; 10(11):935-949. PubMed ID: 30149762
[TBL] [Abstract][Full Text] [Related]
10. CAR T Cells Releasing IL-18 Convert to T-Bet
Chmielewski M; Abken H
Cell Rep; 2017 Dec; 21(11):3205-3219. PubMed ID: 29241547
[TBL] [Abstract][Full Text] [Related]
11. CAIX-specific CAR-T Cells and Sunitinib Show Synergistic Effects Against Metastatic Renal Cancer Models.
Li H; Ding J; Lu M; Liu H; Miao Y; Li L; Wang G; Zheng J; Pei D; Zhang Q
J Immunother; 2020 Jan; 43(1):16-28. PubMed ID: 31574023
[TBL] [Abstract][Full Text] [Related]
12. A second-generation M1-polarized CAR macrophage with antitumor efficacy.
Lei A; Yu H; Lu S; Lu H; Ding X; Tan T; Zhang H; Zhu M; Tian L; Wang X; Su S; Xue D; Zhang S; Zhao W; Chen Y; Xie W; Zhang L; Zhu Y; Zhao J; Jiang W; Church G; Chan FK; Gao Z; Zhang J
Nat Immunol; 2024 Jan; 25(1):102-116. PubMed ID: 38012418
[TBL] [Abstract][Full Text] [Related]
13. The application of HER2 and CD47 CAR-macrophage in ovarian cancer.
Chen Y; Zhu X; Liu H; Wang C; Chen Y; Wang H; Fang Y; Wu X; Xu Y; Li C; Lv X; Huang J; Han X; Li R; Hong W; Yu Z; Wei W; Tu J
J Transl Med; 2023 Sep; 21(1):654. PubMed ID: 37740183
[TBL] [Abstract][Full Text] [Related]
14. In Vitro-Transcribed mRNA Chimeric Antigen Receptor T Cell (IVT mRNA CAR T) Therapy in Hematologic and Solid Tumor Management: A Preclinical Update.
Soundara Rajan T; Gugliandolo A; Bramanti P; Mazzon E
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32899932
[TBL] [Abstract][Full Text] [Related]
15. CAR T Cells for Solid Tumors: New Strategies for Finding, Infiltrating, and Surviving in the Tumor Microenvironment.
Martinez M; Moon EK
Front Immunol; 2019; 10():128. PubMed ID: 30804938
[TBL] [Abstract][Full Text] [Related]
16. Preclinical Models in Chimeric Antigen Receptor-Engineered T-Cell Therapy.
Siegler EL; Wang P
Hum Gene Ther; 2018 May; 29(5):534-546. PubMed ID: 29390873
[TBL] [Abstract][Full Text] [Related]
17. Dual-function chimeric antigen receptor T cells targeting c-Met and PD-1 exhibit potent anti-tumor efficacy in solid tumors.
Yuan X; Sun Z; Yuan Q; Hou W; Liang Q; Wang Y; Mo W; Wang H; Yu M
Invest New Drugs; 2021 Feb; 39(1):34-51. PubMed ID: 32772342
[TBL] [Abstract][Full Text] [Related]
18. A role for multiple chimeric antigen receptor-expressing leukocytes in antigen-specific responses to cancer.
Yong CS; John LB; Devaud C; Prince MH; Johnstone RW; Trapani JA; Darcy PK; Kershaw MH
Oncotarget; 2016 Jun; 7(23):34582-98. PubMed ID: 27153556
[TBL] [Abstract][Full Text] [Related]
19. Improved survival of chimeric antigen receptor-engineered T (CAR-T) and tumor-specific T cells caused by anti-programmed cell death protein 1 single-chain variable fragment-producing CAR-T cells.
Nakajima M; Sakoda Y; Adachi K; Nagano H; Tamada K
Cancer Sci; 2019 Oct; 110(10):3079-3088. PubMed ID: 31432594
[TBL] [Abstract][Full Text] [Related]
20. Chimeric antigen receptor T cell targeting EGFRvIII for metastatic lung cancer therapy.
Zhang Z; Jiang J; Wu X; Zhang M; Luo D; Zhang R; Li S; He Y; Bian H; Chen Z
Front Med; 2019 Feb; 13(1):57-68. PubMed ID: 30721445
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
